1 / 62

Bronchiectasis Questions

Bronchiectasis Questions. Dean E. Schraufnagel, MD ATS President-Elect University of Illinois at Chicago May 6, 2010 Nothing to disclose. ATS Founder. American Thoracic Society: An International Society.

coyne
Télécharger la présentation

Bronchiectasis Questions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bronchiectasis Questions Dean E. Schraufnagel, MD ATS President-Elect University of Illinois at Chicago May 6, 2010 Nothing to disclose

  2. ATS Founder

  3. American Thoracic Society: An International Society • ATS International Conference (May 14-19, 2010 New Orleans) features over 5,500 original research presentations with 16,000 attendees • About half of participants from outside the US • American Journal of Respiratory and Critical Care Medicine has the highest impact factor in respiratory or critical care medicine • Over half of articles submitted to ATS journals come from outside the US

  4. We know about Bronchiectasis … or do we?

  5. Definition?

  6. Definitions • “Permanently” dilated bronchi Reid. Thorax 1950;5:233-47 • 1.5 x larger than accompanying artery Desai et al., Br J Radiol 1994;67:257-62 • Larger than accompanying artery Li et al., Eur Resp J 2005;26:8-14 • What about • Bronchial wall thickness? • Tree in bud? • Reversible?

  7. Is bronchiectasis in different locations different Diseases?

  8. Commonly held • Upper lobe – TB • Middle lobe – environmental mycobacteria • Lower lobe – post-infectious • Central – allergic aspergillosis • Focal – obstruction • Diffuse – agammaglobulinemia

  9. Upper lobe → tuberculosis • Old or active tuberculosis • Unsuspected until hemoptysis • Other upper lobe • Cystic fibrosis • Sarcoidosis • “Dry bronchiectasis” • Post-TB, Sjögren's, unable to expectorate • Yazisiz et al., Rheumatol Int. 2009

  10. Post TB

  11. Mother had TB. Skin test positive

  12. Adult presentation cystic fibrosis

  13. Middle lobe • Middle to older-aged, nonsmoking ♀ • Mitral valve prolapse & chest deformity • Why environmental mycobacteria? • Why middle lobes? • Clearance?

  14. Postnatal respiratory distress + sicca

  15. Allergic bronchopulmonary aspergillosis • Eosinophilia, transient alveolar opacities, ↑IgE (specific), precipitins, immediate skin test • Paradox • Intense inflammation - Rx steroids • But oral steroids ∝ poor outcome • Itraconazole

  16. Lower-lobe How often is it not associated with an etiological Infection?

  17. Focal – Obstruction? • Bronchoscopy? • Other focal areas often present • Important if considering surgery • Gursoy et al., Surgery Today 2010;40:26-30

  18. Diffuse - Immune deficiency? • Immune deficiency • Common variable, HIV • Global airway disease • Mounier Kuhn, papillomatosis, relapsing polychondritis • Advanced bronchiectasis of any type

  19. Why hemoptysis?

  20. ♀ - cc: cough and breathlessness (on questioning-hemoptysis) → Interstitial lung disease → Biopsy

  21. Pathogenesis

  22. Pathogenesis • Secretions not cleared • Organisms grow in secretions • Immune response → ongoing inflammation • Hyperemia, vascular hyperplasia • Bronchospasm • Peribronchial tissue destruction • Upper lobe→ less secretions, less destruction?

  23. Pathogenesis • Organisms remain external to body • Reason for mild symptoms? • Difficulty in treating and diagnosis • Immune cells - less impact • Antibiotics - less penetrance • Little abscesses? • Organisms protected by secretions? • Reason for inadequate treatment?

  24. Excess matrix metalloproteinases • Breakdown tissue • 1607GG allele of promoter MMP1 • ↑ 37 bronchiectasis pts cf 102 nl • Heterozygote O.R. = 5.3 • Homozygotes O.R. = 8.7 • Stankovic et al., J Investig Med 2009;57:500-3

  25. Lung PMN dysfunctional? • Bronchiectatic sputum: ↑ Human neutrophil peptides • ∝Defective phagocytosis • Multiple PMN ∆’s controlled by i.c. Ca2+ • Also found in α1-antitrypsin animal model • Voglis et al., Am J Respir Crit Care Med 2009;180:159-66 • Low neutrophil oxidative burst • IFNγ restores • King et al., APMIS 2009;117:133-39

  26. What about biofilms?

  27. Biofilms • Complicated slime layers • Glycoprotein matrix from bacteria • E.g. dental plaque • Acinetobacter & pseudomonas – more stable than ancestral colonies • Hansen et al., Nature 2007;445:533-6 • M. mucogenicum & B. cepacia→↑biofilm • Simões et al., Appl Environ Microbiol 2007;73:6193-6200

  28. Complex communities • Antagonistic, competitive, commensal, or symbiotic • Benefits • Plasmid sharing • Metabolism sharing • Defense sharing • Disadvantage – nutrient competition • Biofilm mass ↯∝ metabolic activity Simões et al., Appl Environ Microbiol 2007;73:6193-6200

  29. Biofilms Protect inhabitants

  30. Biofilms protect inhabitants • Macrophage engulfment ↓ • Antibiotic penetration ↓ • ↑antibiotic resistance • ↓ stimulation to mucosa • Bacteria switch to latent form • pH, nutrient Δ • Exacerbation - bacteria emerge from biofilm?

  31. Quorum sensing

  32. Quorum sensing • Bacteria ↦molecules ∝ population density • E.g. Gram neg: Acylated homoserine lactones • Sensing → Δ gene expression • ↦ virulence factors, biofilm, antibiotic production, swarming, conjugation, sporulation, bioluminescence • Autoinducer

  33. Treatment potential? • Quorum sensing inhibitors • ↛ gene regulation, production, reception • Enzymes inactivate QS molecules • ↛ biofilm • Fewer toxic effects? • Not required for bacterial growth • Animals and plants →↑survival • Rasmussen & Givskov. Microbiol 2006;152:895-904

  34. Organisms?

  35. Which organisms important? • Most common in established bronchiectasis • H. influenza (47%), P. aeruginosa (12%) • King et al., Resp Med 2007;101:1633-8 • Multiple species • Role of mouth flora? • Role of mycobacteria? • Role of in vitro antibiotic testing?

  36. Low virulent organisms? Low virulence Little damage, invasiveness Living in biofilm different than culture? UIC BAL - stomatococcus ~15% Often “normal respiratory flora” How do deal with it? No growth - adequate sputum? Mycobacteria, fungi, handling problem

  37. Direction?

More Related